Plasma-Based Bioplastic Manufacturing via Low-Temperature Processing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bioplastics for medical implants face challenges such as high temperature processing, degradation independent of the biological environment, lack of adaptability to cellular invasion, and issues with disease transmission and immune response, limiting their clinical effectiveness and safety.
Innovation Solution
A method of making bioplastics using human plasma that is clotted, dried through its gel phase, and processed with a plasticizer, allowing for the incorporation of heat-sensitive materials and control over biomechanical properties, while avoiding high temperature processing and toxic crosslinking agents, and enabling the retention of biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If high temperature processing is used to manufacture bioplastics, then manufacturing precision and material strength are improved, but heat-sensitive biological materials are degraded and biological activity is lost
Solution Approach 1:
The patent changes the temperature parameter from conventional high temperature processing to low temperature processing (below the degradation temperature of biological materials). This allows the formation of bioplastics while preserving heat-sensitive biological materials and maintaining biological activity, resolving the contradiction between material strength and biological activity
Solution Approach 2:
The patent creates composite materials by combining bioplastics with heat-sensitive biological materials (such as growth factors, drugs, or cellular components) in a way that the bioplastic matrix provides structural strength while the biological materials provide functional activity, achieving both strength and biological activity simultaneously
2Stability of the object's composition
If conventional bioplastics are used, then structural stability is achieved, but degradation occurs independently of the biological environment limiting clinical effectiveness
Solution Approach 1:
The patent transforms the degradation process from a static, environment-independent chemical hydrolysis to a dynamic, environment-dependent biological degradation process. The bioplastic is designed to degrade in response to cellular invasion and biological signals, allowing the material to adapt its degradation rate to the healing progress and biological environment
Solution Approach 2:
The bioplastic system enables the material to self-regulate its degradation through interaction with the biological environment. Cellular invasion and biological processes automatically control the degradation rate, eliminating the need for external control mechanisms and allowing the material to serve itself in adapting to the healing process
3Reliability
If purified human fibrinogen from pooled plasma is used, then clinical efficacy is achieved, but disease transmission risk increases
Solution Approach 1:
The patent employs autologous plasma (the patient's own plasma) as the source material, eliminating the need for pooled plasma from multiple donors. This disposable, patient-specific approach ensures clinical efficacy while completely eliminating disease transmission risk, as the material comes from a single, known source
Solution Approach 2:
The patent extracts and uses only the necessary components (plasma proteins that form bioplastics) from the patient's own plasma, separating the beneficial clinical effects from the harmful disease transmission risk that exists in pooled plasma products
4Ease of manufacture
If synthetic bioresorbable plastics are used, then manufacturing ease and cost-effectiveness are improved, but inflammatory interactions increase reducing safety
Solution Approach 1:
The patent changes the material composition parameter from synthetic polymers to protein-based bioplastics derived from plasma. This fundamental material parameter change reduces inflammatory interactions while maintaining manufacturing feasibility through established plasma processing techniques
Solution Approach 2:
The patent uses plasma-derived materials that can be processed using relatively simple, cost-effective methods compared to synthetic polymer manufacturing, while the autologous nature of the material eliminates inflammatory responses, achieving both ease of manufacture and safety
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting plasma-based plastics can degrade in concert with tissue growth, promote host tissue ingrowth, and reduce immune response, offering a cost-effective, adaptable, and safe alternative for medical applications such as graft materials and drug delivery.
Implementation Method 1
human plasma is clotted either before or after any removal of any desired constituents, dried through its gel phase
Implementation Method 2
dried through its gel phase or dried and powdered
Data Source
AI summary
A method of making a bioplastic, and a bioplastic produced thereby, by using human plasma in which human plasma is clotted, either dried through its gel phase or dried and powdered, and processed into a bioplastic with the addition of at least one plasticizer followed by forming and heating to form a final bioplastic construct.